Ftse Mib
38.472,56
0,00%
DAX
22.425,93
0,73%
S&P 500
5.983,25
-0,50%
NASDAQ
19.286,92
-1,21%
Bitcoin
90.663,80
-0,85%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Allarity Therapeutics Inc (ALLR) Allarity Therapeutics Inc (ALLR) Notizie

Allarity Therapeutics Inc

ALLR
0,81
-0,1435 (-15,05%)
25 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/2/202514:00GLOBEAllarity Therapeutics to Begin Enrollment for New Phase 2..
07/2/202514:06EDGAR2Form 8-K - Current report
06/2/202514:00GLOBEAllarity Therapeutics Announces Expansion of Phase 2..
30/1/202514:00GLOBEAllarity Therapeutics Announces Filing of Form 8-K Regarding..
30/1/202513:55EDGAR2Form 8-K - Current report
25/1/202502:09EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
24/1/202522:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202522:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202522:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202522:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/11/202414:00EDGAR2Form 8-K - Current report
18/11/202414:00GLOBEAllarity Therapeutics Reports Key Progress in Phase 2..
14/11/202422:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202414:17EDGAR2Form 8-K - Current report
14/11/202414:00GLOBEAllarity Therapeutics Reports Third Quarter 2024 Financial..
23/10/202414:01EDGAR2Form 8-K - Current report
22/10/202414:00GLOBEAllarity Therapeutics to be Granted European Patent for DRP®..
11/10/202414:00EDGAR2Form 8-K - Current report
10/10/202414:00GLOBEAllarity Therapeutics Regains Compliance with NASDAQ Minimum..
04/10/202414:00EDGAR2Form 8-K - Current report
03/10/202414:00GLOBEAllarity Therapeutics Strengthens Leadership with Key..
01/10/202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/9/202414:00EDGAR2Form 8-K - Current report
16/9/202414:00GLOBEAllarity Therapeutics Announces Two Patients Now Exceeding..
13/9/202414:53EDGAR2Form 8-K - Current report
13/9/202414:45GLOBEAllarity Therapeutics Announces New CFO and Inducement..
11/9/202414:00GLOBEAllarity Therapeutics Takes Decisive Step Toward Regaining..
10/9/202415:15EDGAR2Form 8-K/A - Current report: [Amend]
09/9/202422:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/9/202415:00EDGAR2Form 8-K - Current report
30/8/202422:05EDGAR2Form S-3 - Registration statement under Securities Act of..
21/8/202422:55EDGAR2Form 8-K - Current report
05/8/202423:24EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
26/7/202415:00GLOBEAllarity Therapeutics Announces Postponement of Annual..
26/7/202412:04EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24/7/202412:00GLOBEAllarity Encourages Shareholders to Vote FOR the Reverse..
23/7/202422:05EDGAR2Form 8-K - Current report
22/7/202412:30GLOBEAllarity Therapeutics Outlines Company’s 2024 Progress and..
22/7/202412:03EDGAR2Form 8-K - Current report
27/6/202414:00GLOBEAllarity Granted Hearing Before Nasdaq Panel to Present Plan..
25/6/202414:00GLOBEAllarity Therapeutics’ Dual PARP/Tankyrase Inhibitor,..
06/6/202414:54EDGAR2Form 8-K - Current report
24/5/202414:55EDGAR2Form 8-K/A - Current report: [Amend]
21/5/202414:15EDGAR2Form 8-K - Current report
20/5/202414:00GLOBEAllarity Therapeutics Regains Compliance with Nasdaq's..
17/5/202422:08EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/5/202415:15EDGAR2Form 8-K - Current report
14/5/202422:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202422:01GLOBEAllarity Therapeutics Reports First Quarter Financial..
09/5/202417:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
Apertura: 0,935 Min: 0,76 Max: 0,96
Chiusura: 0,9535

La tua Cronologia

NASDAQ
ALLR
Allarity Therapeutics
AMEX
GSKH
GSK Plc ADRhedged
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci